BioMarin Pharmaceutical | BMRN - Net Income


BioMarin Pharmaceutical reported $-46.57M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Moderna USD -200M 625M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
United Therapeutics USD 338.7M 29.2M Sep/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025